Are chondrocytes damaged when rheumatologic inflammation is suppressed?

Area of Science:

• Rheumatology
• Cell Biology
• Pharmacology

Background:

• Biological agents (BAs) are effective in treating inflammatory joint diseases like rheumatoid arthritis.
• Intra-articular application of BAs is increasingly studied for its effects on cartilage.
• Understanding the molecular-level impact of BAs on chondrocytes is crucial.

Purpose of the Study:

• To comparatively investigate the effects of rituximab, abatacept, and adalimumab on human primary chondrocytes.
• To analyze the molecular-level impact on chondrocyte viability, proliferation, and toxicity.
• To assess the chondrotoxicity of specific approved anti-rheumatic agents.

Main Methods:

• Human primary chondrocytes were cultured from osteochondral tissues of patients undergoing total knee arthroplasty.
• Chondrotoxicity was assessed using flow cytometry and microscopy.
• Cell viability and proliferation were evaluated using MTT assays at 24 and 48 hours.

Main Results:

• The investigated biological agents (rituximab, abatacept, adalimumab) demonstrated chondrotoxicity.
• Significant negative impacts on chondrocyte viability and proliferation were observed (p < 0.01).
• Molecular-level analyses confirmed the toxic effects of these agents on cartilage cells.

Conclusions:

• Approved anti-rheumatic biological agents exhibit toxicity towards chondrocytes.
• Dosage of BAs should consider their cellular-level toxic effects on chondrocytes, especially after inflammation management.
• Further research into mitigating BA-induced chondrocyte toxicity is warranted.